Face in the ad, blood sugar out, install it and it's a $9.99/week logbook: how Glucera makes money

Glucera: Blood Sugar Log (com.begamob.bloodsugar) research report

Date 2026-11-06. Data sources: our googleplay / appstore / googleads / metaads libraries (as of 11-06), App Store and Google Play store pages, third-party estimate sites (paywallscreens, screensdesign), Jina / x-radar / TikHub searches.

One line

A blood sugar logging app from iKame (Begamob Global), an app studio in Hanoi, Vietnam. It only lets you log blood sugar, insulin, medication and A1C by hand, and adds a "Face Scan" module, earning money through a $9.99/week subscription. The iOS version has been live for 8-31 and was first proven in the US. The Android version is the subject of this recall: a copy of the same thing, still in small-scale testing with no large-scale spend.

Verdict

It took off because of the publisher's funnel of "health scan creative for paid acquisition + weekly subscription"; the product itself has nothing special:

• Why users come: a Facebook ad shows someone pointing their phone at their face, and a blood sugar reading appears on screen right away. The hook converts especially well with diabetics and older adults.
• Why users pay: after installing and logging data, a $9.99/week paywall appears, so impulse subscriptions plus forgotten cancellations add up.
• Differentiation: apart from the "face scan" claim in ads, the product is no different from dozens of blood sugar logbooks. The store page itself says "does not measure blood sugar." The real difference lies in the acquisition approach and monetization model: most Android peers rely on ads, while it relies only on subscriptions, with no ads.

1. Data

Android (the subject of this recall)

• Store listing date 2026-08-21. Total global installs 49,602, +7 in the last 12,362 days, 74 ratings (googleplay library 11-06).
• Install curve (AppstoreSpy estimate, app_day_ext): September stayed in single digits to dozens a day, 10-01 total only 89; 10-03 jumped straight to 3,599, then 10-07, 10-12, 10-15 and 10-21 stepped up in tiers, 10-26 to 37,238; after that it slowed to roughly 800 to 1,700 a day. This is a classic paid-acquisition on/off curve, with no sign of organic growth.
• Charts (googleplay library chart_rank): 10-29 charted at #102 on the US Health free chart, then slid to 187,11-05 and dropped off the US charts; its best in Nigeria was #21 (11-02), in the Philippines #41, and it briefly hovered around the top hundred in Saudi Arabia, the UAE, Malaysia and South Africa. Now only ng 93 and ph 177 remain.
• Monetization: no ads (ad_supported = False), in-app purchases from $6.99 to $49.99, subscription only.
• Rating distribution [1 star 19, 2 star 0, 3 star 0, 4 star 2, 5 star 51]: heavy at both ends, thin in the middle, suggesting in-app prompts for good reviews, while some users are angered by the paywall (inferred).
• The privacy policy sits at face-scan-privacy.begamob.com; the store description's feature list includes "Face Scan records"; the disclaimer reads "does not measure blood sugar… Face Scan and all calculated insights are provided for informational and wellness purposes only."

iOS (id 6796661353, the side that actually makes money)

• 2026-08-31 launched, filed under Lifestyle, not Health or Medical (same as sibling Artera; likely to dodge medical app review). Localized Spanish-market name "Glucera: Control de Glucosa", German-market "Blutzucker Tracker".
• US store rating climbed from 10-28 with 887 to 11-06 with 1,018, +10 a day, +101 over 18,7 days; average 4.7 (appstore library). Among US apps whose names contain blood sugar / glucose / diabetes, its 7-day rating growth ranks 2th, just behind TickFlow's HealthPro (+118) and faster than mySugr (+80).
• US store Lifestyle Top Grossing ranks 55 to 75 (10-28 to 11-06); it has charted in the Lifestyle Top Grossing of about 60 countries: Nepal 11, El Salvador 19, Nigeria 21, Uganda 16, Mexico 86 and more. Shows people are paying in many countries, with a global rollout.
• Third-party revenue estimates: paywallscreens (part of Superwall) lists $100K/month and 50K downloads (another snapshot says $30K/month and 30K monthly downloads); screensdesign lists "$210k revenue". All are estimates, unverified.
• App Store reviews (store page, read 11-06):
  • "in the Facebook ad it shows a picture of a person doing a face scan and it immediately provides a blood glucose level. None of his apps including this one will do that… not $10/week."
  • "No sugar reading as developer advertised in Facebook, misleading you to purchase. Not worth 10$ a week."
  • "Glucera advertises that it is a free app. It is until we try to enter our data and you ask for $9.99/week."
  • "Falsely advertised Makes it seem like the face scan will detect blood sugar also"
  • The developer replies with the same line each time: "Glucera is a wellness tracking / journaling app", and one reply promises "we will review our ad creatives".
  • The author of the first review says they've installed several of this developer's apps, which suggests iKame reuses the same creatives and cross-promotes across FaceVital, Artera, iCardiac and Glucera.

II. Competitors

Takeaway: dozens of companies make "blood sugar log books", and on Android the top ones are at tens of millions. Glucera has no feature edge. Compared with the Indian factory apps on Android, it differs in two ways: it monetizes with subscriptions (iOS first) instead of ads, and its ad creatives lead with "face scan".

3. Growth tactics

1. Facebook / Meta ads, leading with "scan your face to test blood sugar" (confirmed): several App Store reviews say they came from Facebook ads, where a face scan shows a blood sugar number. Our metaads library doesn't track this Page, so we can't count the ads.
2. Google app ads (inferred): Google advertiser BEGAMOB GLOBAL LIMITED is running creatives for 18 apps, including sibling Artera (10-02 onward, US only), but we didn't find a creative pointing to Glucera in the previews. The Android curve rises in steps (10-03, 10-07, 10-12, 10-15, 10-21 days jumps), which fits the rhythm of raising UAC budgets, so this is an unverified inference.
3. Cross-promotion across the publisher's portfolio (confirmed): iKame launched FaceVital (06-19), Artera (08-23) and Glucera (08-31) in the health category over 2026 years. Reviews mention users who installed several of the same developer's apps; the privacy policy domain face-scan-privacy is shared.
4. Low-cost small-country chart climbing (confirmed): on Android it has made the health free charts in ng, ph, sa, ae, my and za; on iOS it is in the Lifestyle Top Grossing of about 60 countries, with many small ones (np, sv, ug, ng) in the top 25.
5. Creators, influencers, media (checked, none found): x-radar 60 days, 0 posts; a TikHub search for "glucera" returns only a same-name whitening supplement in Thailand; no press coverage.

Where the money comes from: the paywall is $9.99/week (reviews), Play in-app purchases $6.99 to $49.99. Users must pay to log data at all, so first-week subscriptions cover paid acquisition cost outright, and iOS's high ARPU carries the whole funnel.

4. Visibility

• No founder has posted revenue, no press has covered it, and it isn't discussed on X or TikTok.
• But paywall and UI teardown sites such as paywallscreens ($30K to 100K/month) and screensdesign ($210k) have indexed it with revenue estimates, so peers building subscription apps can see it.
• "Face scan blood sugar" ads are widely discussed in Facebook diabetes groups and called a scam. The Toronto Sun and others have written about misleading diabetes ads on social media, but none named Glucera.
• Classification: circulating in small circles (subscription-app intel sites carry revenue estimates; user communities complain about it).

5. Why it works

1. The same funnel has already been validated inside iKame: iCardiac hit 30k ratings on the US store and charted #19 in Health Top Grossing; the "face scan" creatives for FaceVital and Artera have already worked. Glucera takes that playbook and moves it to blood sugar, a condition where people are willing to pay more.
2. Creative hook: "Point at your face, get your blood sugar." Diabetics find daily finger-pricks painful, so the promise hits a pain point and drives high click-through. The store page and in-app text cover themselves with wellness disclaimers.
3. Monetization: a hard $9.99/week paywall right at entry, and iOS users have strong willingness to pay; Lifestyle Top Grossing ranks 55 to 75 in the US, and about 60 countries chart.
4. Compliance workaround: on iOS it's filed under Lifestyle and called journaling; the Play listing states it does not measure blood sugar, lowering takedown risk.
5. Android is only a country-expansion test: 7 days of +12k, tail positions on small-country charts, far from the stage of scaling spend. The Android signal here is small in itself; the real business is on iOS.

6. What to borrow

• The same product shell (log + charts + reminders + one "scan" gimmick) gets split into multiple branded packs by condition: blood pressure, heart rate, blood sugar, stress (iKame 10-07 just launched Stay: Stress Management). Each pack gets its own paid acquisition, and whichever one works gets more budget.
• iOS first with subscription monetization, Android following, testing small volumes in low-cost countries first.
• Trade low-cost wellness wording and category choice for store-review safety.
• Downside risks: misleading creatives draw concentrated bad reviews, and Apple or Google may take the app down under health-claim policies (the FDA has issued safety notices that smartwatches and rings can't reliably measure blood sugar non-invasively); refunds and bad reviews erode long-term value.

7. Uncertainties

• Actual revenue: third-party estimates run from $30K to $210K/month, a gap of several times.
• How much Meta and Google each spent, and what the creatives actually look like (we haven't seen Glucera creatives in our ad libraries).
• Whether the in-app Face Scan actually gives a blood sugar number, or only heart rate or a "health score" (the store page only says Face Scan records).
• How many of the iOS 4.7 ratings and 1k reviews came from prompted reviews.
• Whether Android gets pushed into US-scale volume.

Sources

• googleplay library: app_profile / app_snap / chart_rank / app_day_ext (AppstoreSpy estimates), 2026-10-29 to 11-06
• appstore library: app_profile, app_day (id 6796661353, US store and about 60 countries)
• googleads library: adv_app (BEGAMOB GLOBAL LIMITED, 18 apps); metaads library not indexed
• App Store reviews page apps.apple.com/us/app/glucera-blood-sugar-tracker/id67966613…
• Play store page play.google.com/store/apps/details?id=com.begamob.bloodsugar
• www.paywallscreens.com/apps/glucera-blood-sugar-tracker-mobi…
• screensdesign.com/apps/glucera-blood-sugar-tracker/
• glucera.app/ (a different product with the same name)
• www.facebook.com/groups/252995116355123/posts/17230820926797… (group discussion asking whether "face scan blood sugar" apps are a scam)
• www.fda.gov/medical-devices/safety-communications/do-not-use…
• Sibling reference: /home/ljr/fanout/why/out/play_com.ikame.bloodpressure.heartrate.monitor.md (Artera)